Daily Dose - Apr 9th, 2024
 
 
Daily Dose | View online
 
April 9, 2024
Data-driven decision-making and analytics capabilities can be the difference between success and failure in pharmaceutical operations. But many companies are missing opportunities to leverage available data.
After withdrawing the BLA for its ALS candidate, BrainStorm will launch a phase 3b trial this year with the FDA's blessing.
Abceutics, a startup rooted in research from the University of Buffalo, focuses on payload-binding selectivity enhancers.
Sponsored
Advanced chemical indicators give you the peace of mind that comes from reliable insights into your supply chains.